Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,339 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the transaction, the insider now directly owns 140,375 shares in the company, valued at $4,849,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $36.59 on Friday. The firm has a market capitalization of $3.20 billion, a P/E ratio of -9.22 and a beta of 1.07. The stock has a 50 day moving average price of $41.07 and a 200-day moving average price of $33.61. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DYN. Nisa Investment Advisors LLC boosted its stake in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after purchasing an additional 796 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in shares of Dyne Therapeutics in the 2nd quarter worth approximately $203,000. Ameritas Investment Partners Inc. grew its stake in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after buying an additional 1,291 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter worth approximately $212,000. 96.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Piper Sandler raised their price target on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Stifel Nicolaus boosted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. upped their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Finally, Guggenheim upped their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.